Alamar Biosciences Inc

News & Events zu Alamar Biosciences Inc (ALMR)

$30.490

+1.174 (+3.85%)Zum Schluss

ALMR-News

ALMR-Events

8/10 17:30

Alamar Biosciences Expands Partnership with Alzheimer's Disease Data Initiative

Alamar Biosciences announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. The expanded agreement adds profiling of 86,000 plasma samples using the company's newest neurology panel, NULISAseq Neuro 220. Approximately 21,000 samples are part of a national-scale proteomics initiative launched with leading research universities in mid-July. Building on the June 2025 announcement of a multi-center initiative which profiled over 55,000 samples using Alamar's ultra-sensitive NULISA technology, this expansion reflects growing confidence in the partnership's scientific output and the Neuro 220 panel's ability to deliver richer insights into the co-pathologies driving neurodegenerative disease. The combined dataset, when completed in 2027, is expected to encompass more than 140,000 samples profiled across multiple geographies and cohorts.

8/10 17:00

Alamar Biosciences Sees FY26 Revenue of $116M-$120M

Alamar Biosciences sees FY26 revenue $116M-$120M, consensus $113.22M

8/10 17:00

Alamar Biosciences Q2 Revenue $29.4M Beats Expectations

Reports Q2 revenue $29.4M, consensus $25.94M. "We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year," said Yuling Luo, CEO of Alamar Biosciences. "With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters."

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten